Type 2 Diabetes Mellitus Completed Phase Trials for Sitagliptin (DB01261)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

DBCOND0029752 (Type 2 Diabetes Mellitus)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01951339Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 DiabetesOther
NCT00673894Effects of Glutamine on GLP-1 and Insulin Secretion in ManTreatment
NCT00775684Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell MassTreatment
NCT01183104START-J: SiTAgliptin in eldeRly Trial in JapanTreatment
NCT01901861Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes
NCT01512797Treatment of Diabetes After Gastric Bypass With SitagliptinTreatment
NCT02628392A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)Treatment
NCT00747383How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.Treatment
NCT01065766Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
NCT01062048Januvia Re-examination Study (MK-0431-181)
NCT01357135An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
NCT02456428Incretin-based Drugs and the Risk of Heart Failure
NCT01624116Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 DiabetesTreatment
NCT01354990A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
NCT01332370Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone
NCT02077946A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
NCT01073826Role of Interleukin-6 in ExercisePrevention
NCT01092663The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes MellitusTreatment
NCT02475499Incretin-based Drugs and Pancreatic Cancer
NCT02476760Incretin-based Drugs and Acute Pancreatitis
NCT00881543Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic PatientsTreatment
NCT01413542Pharmacogenetics of Ace Inhibitor-Associated AngioedemaTreatment